Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
About this item
Full title
Author / Creator
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
The platelet-stimulating agent romiplostim was compared with standard interventions for chronic immune thrombocytopenic purpura. Patients given romiplostim had higher platelet counts, less treatment failure, fewer bleeding episodes, and better quality of life.
Immune thrombocytopenia is an autoimmune disease characterized by low platelet counts...
Alternative Titles
Full title
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_808454165
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_808454165
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1002625
